Tempus AI Stock Insights: Institutional Buying and Stock Volatility
Tempus AI Stock Analysis – In its most recent filing with the Securities and Exchange Commission, Avanza Fonder AB revealed that it purchased 35,414 shares of Tempus AI, Inc. (NASDAQ: TEM) during the fourth quarter. The shares were valued at approximately $1,197,000. This marks a significant move by the fund as it continues to diversify its holdings in the tech and healthcare sectors.
Institutional Investors Show Interest in Tempus AI
Tempus AI has garnered attention from several institutional investors and hedge funds in recent months. For example, Kovitz Investment Group Partners LLC acquired a new position in Tempus AI in Q3, worth approximately $1,367,000. Meanwhile, Sumitomo Mitsui Trust Group Inc. made a notable increase in its stake by 1,591.2% during the same period. The firm now owns 1,217,699 shares of Tempus AI valued at $68,922,000, after purchasing an additional 1,145,698 shares. Other investors, such as Captrust Financial Advisors and Sigma Planning Corp, also raised their positions in the company.
Wall Street Analysts Provide Mixed Opinions on Tempus AI
On Wall Street, several analysts have weighed in on the outlook for Tempus AI. Stifel Nicolaus downgraded the stock from a “buy” to a “hold” rating while raising their price target to $65.00. Piper Sandler, in contrast, reiterated a “neutral” rating, increasing their target price to $70.00. Needham & Company has maintained a “buy” rating with a target price of $56.00, while Bank of America and Wolfe Research also raised their price targets. As of now, Tempus AI holds an average rating of “Moderate Buy” with a target price of $56.36.
Tempus AI Stock Shows Small Gains in Latest Trading Session
In the latest trading session, Tempus AI’s stock rose by 1.2%, reaching $35.15. The stock had a trading volume of 2,434,717 shares, compared to its average volume of 3,412,584. Despite these gains, the stock has faced volatility over the past year, with a 12-month low of $22.89 and a high of $79.49. The company maintains a debt-to-equity ratio of 8.17, with a current ratio of 2.69 and a quick ratio of 2.55, which reflects its liquidity and financial stability.
Insider Activity Signals Potential Changes
In other news, Bradley A. Keywell, a major shareholder in Tempus AI, sold 265,000 shares on January 17th at an average price of $35.10, amounting to a total of $9,301,500. Following the sale, Keywell now owns 15,218,365 shares valued at approximately $534,164,611.50. Similarly, COO Ryan Fukushima sold 120,000 shares on December 11th, worth $5,101,200.00. These insider transactions indicate a 1.71% decrease in Keywell’s ownership, and a 10.65% decrease in Fukushima’s stake.
Tempus AI: A Leader in Precision Medicine and AI Technology
Tempus AI, Inc. is a technology company focused on advancing precision medicine through the practical application of artificial intelligence. The company specializes in providing AI-enabled healthcare solutions to physicians, helping them deliver personalized patient care. Additionally, Tempus plays an active role in facilitating the discovery, development, and delivery of optimal therapeutics, positioning itself as a leader in the growing field of healthcare innovation.
Tempus AI’s Position in the Market
As Tempus AI continues to develop and expand its offerings in precision medicine and AI technologies, its stock remains a subject of interest among institutional investors, analysts, and traders. The mixed views from analysts and recent insider activity signal that Tempus AI is an evolving player in the market, with the potential for growth and volatility in the near future. However, its long-term prospects will depend on how well the company continues to innovate within the healthcare sector.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Cryptocurrencies and stocks, particularly in micro-cap companies, are subject to significant volatility and risk. Please conduct thorough research before making any investment decisions.
Leave a comment